Organogenesis (NASDAQ:ORGO) Price Target Cut to $2.00 by Analysts at Truist Financial

Organogenesis (NASDAQ:ORGO) had its target price decreased by stock analysts at Truist Financial from $3.00 to $2.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s price objective suggests a potential upside of 14.16% from the stock’s current price.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, UBS Group set a $3.00 target price on shares of Organogenesis in a research note on Thursday, May 28th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Organogenesis presently has an average rating of “Hold” and a consensus price target of $5.50.

Organogenesis Trading Down 27.3%

Shares of NASDAQ ORGO opened at $1.75 on Friday. The company has a market cap of $225.45 million, a price-to-earnings ratio of -9.52 and a beta of 1.34. Organogenesis has a 12-month low of $1.99 and a 12-month high of $7.08. The company has a current ratio of 3.53, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. The stock’s 50 day simple moving average is $2.44 and its 200 day simple moving average is $2.77.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36). The company had revenue of $43.76 million for the quarter, compared to analyst estimates of $54.27 million. Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Organogenesis during the third quarter valued at approximately $25,000. Flagship Harbor Advisors LLC acquired a new position in Organogenesis in the 4th quarter worth approximately $34,000. Federated Hermes Inc. grew its position in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after purchasing an additional 2,953 shares in the last quarter. Walleye Capital LLC purchased a new position in Organogenesis during the 2nd quarter worth approximately $45,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Organogenesis during the 4th quarter valued at $57,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.